Published in Blood Weekly, January 29th, 2004
Researchers in England "developed a sensitive, competitive, nested reverse transcription polymerase chain reaction (RT-PCR) titration assay that quantifies the number of Wilm's tumor (WT1) gene transcripts in bone marrow (BM) and peripheral blood (PB), coupled with a competitive RT-PCR protocol for the ABL gene as control."
M. Garg and colleagues at the University of Manchester "studied BM/PB samples from 107 acute myeloid leukemia (AML) patients and 22 acute lymphoblastic leukemia (ALL) patients at presentation and detected the WT1 gene in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.